AstraZeneca COVID Drug Performs Well Against Omicron Subvariants: Study

AstraZeneca COVID Drug Performs Well Against Omicron Subvariants: Study
A worker packages the AstraZeneca’s Evusheld medication in an undated video. AstraZeneca via AP
Zachary Stieber
Zachary Stieber
Senior Reporter
|Updated:

A COVID-19 drug made by AstraZeneca did nearly as well against subvariants of the Omicron virus variant as the main variant, according to a new study.

Researchers with AstraZeneca, the Washington University School of Medicine, and other institutions used mice to test the monoclonal antibody combination, known as Evusheld, and a drug made by Vir Biotechnology, against the subvariants which have been increasing in prevalence in the United States.

Zachary Stieber
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
twitter
truth
Related Topics